{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-270884","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.352551+00:00","generated_at":"2026-06-08T19:05:31.519831+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Madrigal Q3 operating expenses $98.5M; FDA Priority Review for resmetirom; $500M October financing","bullets":["FDA accepted NDA for resmetirom, granted Priority Review; PDUFA date March 14, 2024; no advisory committee planned.","Bill Sibold appointed CEO in Sep 2023; previously EVP at Sanofi, led Dupixent launch.","$500M public offering closed Oct 2023; net proceeds $472M for pre-launch activities.","Cash and securities $232.4M as of Sep 30, 2023, prior to October offering.","Q3 2023 operating expenses $98.5M ($71.0M R&D, $27.6M G&A); nine-month total $263.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-270884","json":"https://secwatch.observer/filing/0001193125-23-270884.json","markdown":"https://secwatch.observer/filing/0001193125-23-270884.md","text":"https://secwatch.observer/filing/0001193125-23-270884.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523270884/0001193125-23-270884-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523270884/d583670d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T19:05:31.519831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"834334a75a0a1431eb6100e745933a2dcb2874ad","claim":"MADRIGAL PHARMACEUTICALS, INC. reported financial results for third quarter 2023.","evidence_excerpt":"On November 6, 2023, Madrigal Pharmaceuticals, Inc. (the \"Company\") issued a press release announcing the Company’s financial results for the fiscal quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000119312523270884/0001193125-23-270884-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}